GLP-1 TV · Patient story · views checked Oct 2026
LIFEMD CEO: NOT Just A GLP-1 Company, They Are HealthCare Platform ($LFMD Impact Stock)
Our summary
In this interview, Tim of Alpha Wolf Capital talks with Justin Shriber, CEO of LifeMD, about how the company describes itself and where it is heading in 2026. The host says the video is for education and entertainment and is not investment advice. Shriber says LifeMD is not a weight loss company. He describes GLP-1 care as one vertical on a virtual primary care platform that also covers urgent care, specialty care, labs and pharmacy, with 75,000 patients or more on the platform.
One person's experience, in their words. Not medical advice.
Where GLP-1 costs least today
The three cheapest partner programs for GLP-1, all in per month, checked weekly.
What else the video covers
On GLP-1 medications, Shriber says LifeMD chose collaborations with Eli Lilly and Novo Nordisk for the longer term. He says lower self-pay prices from both drugmakers are straining compounders. He expects Medicare coverage and more FDA attention to compounding pharmacies, and he predicts some enforcement activity in 2026. He also says LifeMD has a mail order pharmacy licensed in all 50 states and a 503A compounding license, and that it does not compound GLP-1 therapies.
Shriber also discusses the business more broadly. He says the first two employers have signed up to pay for LifeMD care or pharmacy, and insurance and Medicare are being turned on. He gives retention figures: some early weight management cohorts had 50% one-year retention, while three and six month cohorts sit around 30%. He sets a 50% one-year goal for women's health. He covers quality control across states, lawsuits he calls routine, the Work Simply sale, why he did not raise capital, and his 10b5-1 plan. He says he is confident about 2026.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 2:41 Shriber says GLP-1 care is one vertical of LifeMD's virtual primary care platform, which he says has 75,000 patients or more.
- 4:13 He says LifeMD chose collaborations with Eli Lilly and Novo Nordisk for the long term and expects some enforcement activity against compounders in 2026.
- 5:45 He names provider shortages and access to care as the biggest problem in US healthcare and says LifeMD offers longitudinal primary and specialty care at scale.
- 12:22 He says LifeMD signed its first two paying employers this quarter and plans to build an enterprise team in 2026.
- 13:54 He says LifeMD is licensed as a mail order pharmacy in all 50 states and holds a 503A compounding license, but does not compound GLP-1 therapies.
- 33:22 He says some early weight management cohorts reached 50% one-year retention, while three and six month cohorts are around 30%, and he targets 50% for women's health.
Key moments
From the creator's own chapters. Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Prices mentioned
- $10,000 a year
- Who is speaking
- Patient
Questions this video answers
Does LifeMD compound GLP-1 medications?
According to Shriber, LifeMD does not compound GLP-1 therapies. He says the company recently got a 503A compounding license and uses it for other personalized therapies, which he expects to be a bigger part of the business in 2026.
Why did LifeMD partner with Eli Lilly and Novo Nordisk?
Shriber says the company took a longer term view when forming its collaborations with Lilly and Novo Nordisk. He says lower self-pay prices from both drugmakers are putting strain on compounders. He also expects Medicare coverage and FDA scrutiny of compounding pharmacies to follow.
Is LifeMD only a weight loss or GLP-1 company?
Shriber says no. He describes LifeMD as a virtual primary care platform with urgent care, specialty care, labs and pharmacy, where GLP-1 care is one vertical. He says the company wants four or five growing verticals rather than depending on one.
What are LifeMD's patient retention rates for weight management?
Shriber says some early weight management cohorts had one-year retention of 50%. He says three and six month cohorts are closer to 30% at a year, and some one-month subscribers retain much worse. He says the 30% figure is roughly where the wider virtual care industry sits.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
LifeMD Crashes -27% on GLP-1 Fears... Why I'm Buying The Dip! (LFMD Stock Analysis)The creator of the Beat The Denominator channel explains why they bought LifeMD (LFMD) after the stock fell 27% on a Friday.
Eli Lilly Just Proved GLP-1 Prices Could Be Lower… Here’s the Chart!According to the video, Christopher Durham of the DOWNSIZED channel walks through 10 points from Eli Lilly's Q1 2026 earnings call, held April 30, 2026, and translates them for patients.
HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVOThis Schwab Network segment features two analysts discussing Hims and Hers after its latest quarterly report: Christine Short, head of research at TMX Data Links, and Brian Tanquilut, managing director for healthcare research at Jefferies.
GLP-1 Drugs Are About to Destroy Medicare CostsAccording to the video, Medicare will begin covering weight loss drugs such as Wegovy and Zepbound in July 2026 through a temporary route, and the speaker argues this could change the math behind Medicare premiums.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Is LifeMD legit for weight loss? The program fee, the drug prices, and the reviews
Yes. As of October 2026 LifeMD is a real telehealth company: affiliated licensed providers prescribe branded GLP-1s such as Wegovy and Zepbound, its pages carry a LegitScript seal, it scores 3.9 on Trustpilot from 4,270 reviews, and FDA's warning-letter database lists no letter to it. The catch is cost. The weight program is $39 for the first month and $149 a month after that. The drug is billed on top: Wegovy pen from $199, Zepbound vial from $299.
- GLP-1 patient assistance programs: what Lilly Cares and Novo's PAP actually cover
Both makers run free-drug programs for people with low income and no insurance or Medicare, but neither covers its weight-loss GLP-1. Novo Nordisk's Patient Assistance Program supplies Ozempic injections free to uninsured patients at or below 200% of the federal poverty level, and lists no Wegovy and no pills. Lilly Cares lists Trulicity as its only GLP-1: no Mounjaro, no Zepbound, no Foundayo. For weight loss, the realistic low-cost routes are the Medicare GLP-1 Bridge at $50 a month and the cash market.
- Foundayo: the GLP-1 pill where buying direct is the cheap route
Lilly's oral GLP-1 was approved on 1 April 2026, and it does something no other weight-loss pill does: you take it any time of day, with or without food. The pricing is the surprising part. Lilly self-pay starts at $149 a month, and the one telehealth program on our board selling it, Sesame Care, charges $208 once its membership fee is counted. That reverses the usual arithmetic in this market, and the reason is simple: orforglipron is a new small molecule under patent, so there is no compounded version to undercut it.
Find more like it
Cost and insuranceStopping and maintenance
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.